We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effects of Theobromine and Caffeine on Mood, Cognition and Blood Pressure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01288547
Recruitment Status : Completed
First Posted : February 2, 2011
Last Update Posted : February 23, 2012
Information provided by (Responsible Party):
Unilever R&D

Brief Summary:
The purpose of this study was to measure potential mood, cognition and blood pressure effects of theobromine and caffeine in healthy women

Condition or disease Intervention/treatment
Mood Dietary Supplement: theobromine Dietary Supplement: Caffeine Dietary Supplement: caffeine + theobromine Dietary Supplement: placebo

Detailed Description:

Background Previous research has shown that naturally occurring chocolate ingredients theobromine and caffeine have positive effects on mood.

Objectives: To assess mood and cognition in adult subjects after the consumption of capsules filled with 1. placebo, 2. theobromine alone, 3. caffeine alone or, 4. theobromine and caffeine combined together.

Study design: Double-blind, placebo-controlled, randomized, cross-over design, with a 1 week washout period in between.

During the 4 weeks intervention period, once a week one of the 4 types of test products were consumed with 250ml of water in a randomized order;

  1. placebo capsules
  2. theobromine capsules (700 mg),
  3. caffeine capsules (120 mg),
  4. mix of theobromine (700 mg) and caffeine (120 mg). Twenty-four healthy female subjects (and 4 reserve subjects) were recruited for a four week intervention period in total with every week a 4 hrs measurement day and one of the interventions.

Primary parameters: mood (via a Bond-Lader/ caffeine visual analogue questionnaire), cognition (Digit Symbol substitution) Secondary parameters: blood pressure

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: Temporal Change of Mood and Cognition in Healthy Subjects After Consumption of Theobromine and/ or Caffeine
Study Start Date : May 2008
Primary Completion Date : June 2008
Study Completion Date : July 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Caffeine
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: theobromine
theobromine (700 mg) in capsule
Dietary Supplement: theobromine
700 mg theobromine in gelatin capsules given one time only
Other Name: 3,7-dimethylxanthine
Active Comparator: caffeine
caffeine (120 mg) in capsule
Dietary Supplement: Caffeine
120 mg caffeine in capsules given one time only
Other Name: 1,3,7-trimethylxanthine
Placebo Comparator: Placebo capsule
no theobromine or caffeine
Dietary Supplement: placebo
cellulose in capsules given one time only
Other Name: avicel (cellulose)
Active Comparator: theobromine + caffeine
Combined theobromine and caffeine treatment, consisting of 700 mg theobromine and 120 mg caffeine
Dietary Supplement: caffeine + theobromine
120 mg caffeine and 700 mg theobromine in capsules given one time only
Other Name: methylxanthines

Primary Outcome Measures :
  1. Mood and cognition [ Time Frame: 3 hrs every week for 4 weeks ]

    Bond Lader Visual Analogue Scale

    Digit Symbol Substitution

    Caffeine Negative Symptoms

Secondary Outcome Measures :
  1. blood pressure and heart rate [ Time Frame: 3 hrs every week for 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Female
  • Age at start of study 18 till 70 years
  • Body Mass Index (BMI) between 20 and 30 kg/m2 inclusive
  • Reported alcohol consumption for females < 21
  • Willing to refrain from caffeine and theobromine for 24 hours
  • Apparently healthy: no reported current or previous metabolic diseases, chronic gastrointestinal disorders, cardiovascular or psychiatric disease which might effect study measurements assessed by Research physician
  • willing to consume animal foods products (gelatine).
  • Consumes caffeine (7 cups of either tea, cola or coffee per week minimum)
  • Having a general practitioner (GP)

Exclusion Criteria:

  • Being an Unilever employee
  • Blood pressure above 160/90 mmHg at screening and irregular heart rate
  • Using or planning to use any medically prescribed diet or weight-loss diet
  • Reported intense sporting activities > 10 h/w
  • Subjects who undergoing medical treatment that may interfere with the study outcome.
  • Reported weight change ± 10% during a period of 6 months prior to the study
  • Reported intolerance or allergy for one of test products or standardized meal
  • The habit of smoking during the past half year, drug use during the past half year or using nicotine containing medicines during the past month
  • Reported lactating (or lactating < 6 weeks ago), pregnant (or pregnant < 3 months ago) or wish to become pregnant during the study
  • Not able to perform the computer tasks assessed during screening
  • Reported participation in night shift work during the study period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01288547

Unilever Discover
Vlaardingen, Zuid Holland, Netherlands, 3130 AC
Sponsors and Collaborators
Unilever R&D
Principal Investigator: Yvonne Zebregs Unilever R&D

Responsible Party: Unilever R&D
ClinicalTrials.gov Identifier: NCT01288547     History of Changes
Other Study ID Numbers: 07045V
First Posted: February 2, 2011    Key Record Dates
Last Update Posted: February 23, 2012
Last Verified: February 2012

Keywords provided by Unilever R&D:

Additional relevant MeSH terms:
Central Nervous System Stimulants
Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Vasodilator Agents